Randomized
\(n = 141\)

Allocated to intervention \(n = 78\)
- Followed \(n = 78\)
  - Lost to follow-up \(n = 0\)

Allocated to control condition \(n = 63\)
- Followed \(n = 63\)
  - Lost to follow-up \(n = 0\)

With primary outcome \(n = 75\)
- Analysed \(n = 71\)
  - Excluded from analysis \(n = 7\)
    - Reasons:
      - 4 not sufficient baseline data
      - 1 not sufficient intervention data
      - 2 not sufficient both periods

With primary outcome \(n = 56\)
- Analysed \(n = 52\)
  - Excluded from analysis \(n = 8\)
    - Reasons:
      - 4 not sufficient baseline data
      - 3 not sufficient intervention data
      - 1 not sufficient both periods

Followed \(n = 74\)
- Lost to 6m follow-up \(n = 4\)
  - Reasons:
    - 1 dead (during intervention period)
    - 3 discharged from services

Followed \(n = 58\)
- Lost to 6m follow-up \(n = 5\)
  - Reasons:
    - 1 withdrawn (baseline)
    - 2 withdrew (baseline)
    - 1 moved abroad (during 6m follow-up)
    - 1 not in community

With primary outcome \(n = 61\)
- Analysed \(n = 58\)
  - Excluded from analysis \(n = 16\)
    - Reasons:
      - 5 no depot data in one or both periods
      - 3 not sufficient baseline data
      - 6 not sufficient follow-up data
      - 2 not sufficient both periods

With primary outcome \(n = 45\)
- Analysed \(n = 41\)
  - Excluded from analysis \(n = 17\)
    - Reasons:
      - 5 no depot data in one or both periods
      - 1 not sufficient baseline data
      - 9 not sufficient follow-up data
      - 2 not sufficient both periods
      - 1 oral medication only

Followed \(n = 75\)
- Lost to follow-up \(n = 1\)
  - Reasons:
    - 1 discharged to GP

Followed \(n = 55\)
- Lost to follow-up \(n = 4\)
  - Reasons:
    - 2 discharged to GP
    - 1 died
    - 1 not in community
With primary outcome \( n = 66 \)
Analysed \( n = 66 \)
Excluded from analysis \( n = 9 \)
Reasons:
3 no depot data
3 not sufficient depot data
3 oral medication only

With primary outcome \( n = 50 \)
Analysed \( n = 49 \)
Excluded from analysis \( n = 6 \)
Reasons:
1 no depot data
2 not sufficient depot data
3 oral medication only

Figure 1 Consort diagram illustrating participant flow across the different stages of the trial
Table 1 Socio-demographic and clinical characteristics at baseline, end of intervention, and 6- and 24-month follow-ups.

<table>
<thead>
<tr>
<th>Demographics</th>
<th>Baseline</th>
<th>End of Intervention</th>
<th>6-month follow-up</th>
<th>24-month follow-up</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Incentives (N=78)</td>
<td>Control (N = 63)</td>
<td>Incentives (N = 77)</td>
<td>Control (N = 60)</td>
</tr>
<tr>
<td></td>
<td>mean or n</td>
<td>SD or %</td>
<td>mean or n</td>
<td>SD or %</td>
</tr>
<tr>
<td>Age (years)</td>
<td>44.4 9.6 42.7 10.2</td>
<td>45.2 9.3 43.3 10.0</td>
<td>45.6 9.3 43.7 10.0</td>
<td>47.2 9.3 45.5 9.9</td>
</tr>
<tr>
<td>Male sex</td>
<td>59 76% 46 73%</td>
<td>59 76% 45 76%</td>
<td>58 76% 46 77%</td>
<td>59 77% 45 76%</td>
</tr>
<tr>
<td>Ethnicity</td>
<td>White</td>
<td>49 63% 34 57%</td>
<td>49 63% 33 56%</td>
<td>47 62% 34 57%</td>
</tr>
<tr>
<td></td>
<td>Black</td>
<td>17 22% 14 23%</td>
<td>17 22% 14 24%</td>
<td>17 22% 14 23%</td>
</tr>
<tr>
<td></td>
<td>Asian</td>
<td>5 6% 4 7%</td>
<td>5 6% 4 7%</td>
<td>5 7% 4 7%</td>
</tr>
<tr>
<td></td>
<td>Mixed and other</td>
<td>7 9% 8 13%</td>
<td>7 9% 8 14%</td>
<td>7 9% 8 13%</td>
</tr>
<tr>
<td>Living situation</td>
<td>Married/co-habiting</td>
<td>8 10% 10 16%</td>
<td>8 10% 7 12%</td>
<td>6 8% 8 13%</td>
</tr>
<tr>
<td></td>
<td>Independent accommodation</td>
<td>53 68% 49 83%</td>
<td>53 68% 50 85%</td>
<td>52 68% 47 81%</td>
</tr>
<tr>
<td></td>
<td>Living alone</td>
<td>41 62% 34 62%</td>
<td>43 55% 35 59%</td>
<td>40 63% 34 64%</td>
</tr>
<tr>
<td></td>
<td>Paid employment (any)</td>
<td>3 4% 1 2%</td>
<td>4 5% 0 0%</td>
<td>4 5% 2 3%</td>
</tr>
<tr>
<td></td>
<td>Receiving benefits</td>
<td>76 99% 58 100%</td>
<td>70 97% 54 98%</td>
<td>70 97% 57 97%</td>
</tr>
<tr>
<td>Diagnosis</td>
<td>Schizophrenia</td>
<td>61 78% 52 82%</td>
<td>56 81% 45 83%</td>
<td>57 75% 45 75%</td>
</tr>
<tr>
<td></td>
<td>Schizo-affective disorders</td>
<td>9 12% 8 12%</td>
<td>8 12% 5 9%</td>
<td>11 14% 11 18%</td>
</tr>
<tr>
<td></td>
<td>Bipolar affective disorder</td>
<td>6 8% 1 2%</td>
<td>4 6% 3 6%</td>
<td>5 7% 3 5%</td>
</tr>
<tr>
<td></td>
<td>Other psychosis</td>
<td>2 2% 1 2%</td>
<td>1 1% 0 0%</td>
<td>2 3% 0 0%</td>
</tr>
<tr>
<td></td>
<td>Other diagnosis</td>
<td>0 0% 1 2%</td>
<td>0 0% 1 2%</td>
<td>1 1% 1 2%</td>
</tr>
<tr>
<td>Clinical history</td>
<td>Duration of illness (years)</td>
<td>18.2 8.6 17.3 8.5</td>
<td>19.2 8.6 18.3 8.6</td>
<td>19.9 8.6 18.8 8.5</td>
</tr>
<tr>
<td></td>
<td>Number of psychiatric hospitalisations over assessment period</td>
<td>0.9 2.7 59 0.6</td>
<td>0.7 1.4 0.6 1.4</td>
<td>0.3 0.7 0.2 0.6</td>
</tr>
</tbody>
</table>
Table 2 Treatment cycles during baseline, intervention period, during the two follow-up periods.

<table>
<thead>
<tr>
<th>Depot cycle</th>
<th>Baseline</th>
<th>End of Intervention</th>
<th>1-6m Follow-up</th>
<th>7-24m Follow-up</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Incentives N</td>
<td>%</td>
<td>Control N</td>
<td>%</td>
</tr>
<tr>
<td>1/52</td>
<td>4</td>
<td>5.6</td>
<td>3</td>
<td>5.5</td>
</tr>
<tr>
<td>2/52</td>
<td>50</td>
<td>69.4</td>
<td>34</td>
<td>61.8</td>
</tr>
<tr>
<td>3/52</td>
<td>5</td>
<td>6.9</td>
<td>2</td>
<td>3.6</td>
</tr>
<tr>
<td>4/52</td>
<td>12</td>
<td>16.7</td>
<td>13</td>
<td>23.6</td>
</tr>
<tr>
<td>Variable</td>
<td>1</td>
<td>1.4</td>
<td>3</td>
<td>5.5</td>
</tr>
<tr>
<td>Total</td>
<td>72</td>
<td>100</td>
<td>55</td>
<td>100</td>
</tr>
</tbody>
</table>
Table 3: Adherence by treatment cycle at baseline, during the intervention period, and during both follow-up periods.

<table>
<thead>
<tr>
<th>Treatment cycle</th>
<th>Baseline period (N=123)</th>
<th>Intervention period (N=123)</th>
<th>1-6-month follow-up (N=110)</th>
<th>7-24-month follow-up (N=110)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Incentives N=71</td>
<td>Control, (N=52)</td>
<td>Incentives N=71</td>
<td>Control, (N=52)</td>
</tr>
<tr>
<td></td>
<td>N</td>
<td>Mean adherence</td>
<td>N</td>
<td>Mean adherence</td>
</tr>
<tr>
<td>1/52</td>
<td>2</td>
<td>54%</td>
<td>1</td>
<td>45%</td>
</tr>
<tr>
<td>2/52</td>
<td>49</td>
<td>67%</td>
<td>27</td>
<td>68%</td>
</tr>
<tr>
<td>3/52</td>
<td>4</td>
<td>76%</td>
<td>3</td>
<td>66%</td>
</tr>
<tr>
<td>4/52</td>
<td>12</td>
<td>76%</td>
<td>16</td>
<td>66%</td>
</tr>
<tr>
<td>5/52</td>
<td>n/a</td>
<td>n/a</td>
<td>n/a</td>
<td>n/a</td>
</tr>
<tr>
<td>Variable cycle</td>
<td>4</td>
<td>60%</td>
<td>5</td>
<td>62%</td>
</tr>
</tbody>
</table>

Note: n/a = not applicable
Table 4 Primary and secondary outcomes at baseline, end of intervention, and 6- and 24-months follow-ups.

<table>
<thead>
<tr>
<th>Period</th>
<th>Incentives</th>
<th>Control</th>
<th>Type of effect estimate</th>
<th>Adjusted effect estimate</th>
<th>P-value</th>
<th>ICC (^{\dagger})</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Primary outcome</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Adherence (percentage)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>to depot medication</td>
<td>Baseline</td>
<td>72</td>
<td>69% (16%)</td>
<td>55</td>
<td>67% (16%)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>12-month intervention</td>
<td>75</td>
<td>85% (15%)</td>
<td>56</td>
<td>71% (22%)</td>
<td>Difference in means</td>
</tr>
<tr>
<td></td>
<td>1-6-month follow-up</td>
<td>58</td>
<td>70% (24%)</td>
<td>41</td>
<td>77% (19%)</td>
<td>Difference in means</td>
</tr>
<tr>
<td></td>
<td>7-24-month follow-up</td>
<td>66</td>
<td>68% (21%)</td>
<td>50</td>
<td>74% (19%)</td>
<td>Difference in means</td>
</tr>
<tr>
<td>Achieving at least 95% adherence versus not</td>
<td>Baseline</td>
<td>72</td>
<td>5 (7%)</td>
<td>55</td>
<td>1 (2%)</td>
<td>Odds ratio (^{\dagger})</td>
</tr>
<tr>
<td></td>
<td>12-month intervention</td>
<td>75</td>
<td>21 (28%)</td>
<td>56</td>
<td>3 (5%)</td>
<td>Odds ratio (^{\dagger})</td>
</tr>
<tr>
<td></td>
<td>1-6-month follow-up</td>
<td>66</td>
<td>5 (8%)</td>
<td>54</td>
<td>9 (17%)</td>
<td>Odds ratio (^{\dagger})</td>
</tr>
<tr>
<td></td>
<td>7-24-month follow-up</td>
<td>66</td>
<td>4 (6%)</td>
<td>50</td>
<td>5 (10%)</td>
<td>Odds ratio (^{\dagger})</td>
</tr>
<tr>
<td>At least one psychiatric hospital admission</td>
<td>Baseline</td>
<td>78</td>
<td>14 (19%)</td>
<td>60</td>
<td>10 (17%)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>12-month intervention</td>
<td>78</td>
<td>15 (19%)</td>
<td>59</td>
<td>14 (24%)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>1-6-month follow-up</td>
<td>74</td>
<td>15 (20%)</td>
<td>58</td>
<td>8 (14%)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>7-24-month follow-up</td>
<td>77</td>
<td>24 (31%)</td>
<td>60</td>
<td>10 (17%)</td>
<td></td>
</tr>
<tr>
<td>At least one suicide attempt versus none</td>
<td>Baseline</td>
<td>78</td>
<td>9 (12%)</td>
<td>59</td>
<td>7 (12%)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>12-month intervention</td>
<td>77</td>
<td>8 (10%)</td>
<td>58</td>
<td>4 (7%)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>1-6-month follow-up</td>
<td>73</td>
<td>3 (4%)</td>
<td>58</td>
<td>3 (5%)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>7-24-month follow-up</td>
<td>75</td>
<td>5 (7%)</td>
<td>58</td>
<td>3 (5%)</td>
<td></td>
</tr>
<tr>
<td>At least one violent incident versus none</td>
<td>Baseline</td>
<td>77</td>
<td>15 (20%)</td>
<td>60</td>
<td>10 (17%)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>12-month intervention</td>
<td>77</td>
<td>10 (13%)</td>
<td>58</td>
<td>7 (12%)</td>
<td></td>
</tr>
<tr>
<td>Outcome</td>
<td>Baseline</td>
<td>12-month intervention</td>
<td>1-6-month follow-up</td>
<td>7-24-month follow-up</td>
<td></td>
<td></td>
</tr>
<tr>
<td>---------------------------------</td>
<td>----------</td>
<td>-----------------------</td>
<td>---------------------</td>
<td>----------------------</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>77</td>
<td>77</td>
<td>73</td>
<td>75</td>
<td></td>
<td></td>
</tr>
<tr>
<td>At least one police arrest versus none</td>
<td>13</td>
<td>10</td>
<td>6</td>
<td>14</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>(18%)</td>
<td>(13%)</td>
<td>(6%)</td>
<td>(19%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>60</td>
<td>60</td>
<td>58</td>
<td>58</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>(16%)</td>
<td>(17%)</td>
<td>(5%)</td>
<td>(5%)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

* n is the number of patients in either group with both a baseline and follow up period for the specified outcome
† Number of patients during 6-month follow-up: Excludes 9 patients on whom no data were collected during the 6 month follow up period: 2 who withdrew immediately after randomisation and 1 who was withdrawn as was not being prescribed depot medication, 1 who died during the intervention period, 2 who were discharged during the intervention period, 1 who was discharged during the 6 follow up period, 1 who moved abroad during follow up and 1 who was out of the community for all of the follow up period.
‡ Number of patients during 24-month follow-up. Excludes 4 patients who were lost to follow-up before the start of the 6 months follow-up period. Of the remaining 137 patients, 5 were lost during the 6 month follow up and a further 5 were lost to follow-up during the final phase of the study. Four patients lost during the 6-month follow up returned to the study.
¥ Each model was adjusted for baseline measure of outcome, MINI score category (low vs. high) and average treatment cycle during baseline, and includes a random effect for team.
Table 5 Sensitivity analysis of primary outcome at the two follow-up periods

<table>
<thead>
<tr>
<th>Analysis population</th>
<th>1-6-month follow-up</th>
<th>7-24-month follow-up</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>N</td>
<td>Difference in mean adherence</td>
</tr>
<tr>
<td>Main analysis: all participants with ≥ 4 months’ depot data</td>
<td>108</td>
<td>-6.2%</td>
</tr>
<tr>
<td>All participants as above, setting adherence to 100% for those discharged to GP</td>
<td>130</td>
<td>-5.0%</td>
</tr>
<tr>
<td>All participants as above but setting adherence to 0% for refusers</td>
<td>112</td>
<td>-4.9%</td>
</tr>
</tbody>
</table>

Note: * Simple linear regression model including only a fixed effect for intervention versus control. Clustering by team ignorable as the ICC was -0.05; ** Linear mixed effects model including only a fixed effect for intervention versus control. The model-based ICC was <0.001.
Table 2 Treatment cycles during baseline, intervention period, during the two follow-up periods.

<table>
<thead>
<tr>
<th>Depot cycle</th>
<th>Baseline</th>
<th>End of Intervention</th>
<th>1-6m Follow-up</th>
<th>7-24m Follow-up</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Incentives</td>
<td>Control</td>
<td>Incentives</td>
<td>Control</td>
</tr>
<tr>
<td>1/52</td>
<td>4</td>
<td>5.6</td>
<td>2</td>
<td>2.7</td>
</tr>
<tr>
<td></td>
<td>3</td>
<td>5.5</td>
<td>1</td>
<td>1.8</td>
</tr>
<tr>
<td>2/52</td>
<td>50</td>
<td>69.4</td>
<td>51</td>
<td>68.0</td>
</tr>
<tr>
<td></td>
<td>34</td>
<td>61.8</td>
<td>29</td>
<td>51.8</td>
</tr>
<tr>
<td>3/52</td>
<td>5</td>
<td>6.9</td>
<td>4</td>
<td>5.3</td>
</tr>
<tr>
<td></td>
<td>2</td>
<td>3.6</td>
<td>3</td>
<td>5.4</td>
</tr>
<tr>
<td>4/52</td>
<td>12</td>
<td>16.7</td>
<td>13</td>
<td>17.3</td>
</tr>
<tr>
<td></td>
<td>13</td>
<td>23.6</td>
<td>18</td>
<td>32.1</td>
</tr>
<tr>
<td>Variable</td>
<td>1</td>
<td>1.4</td>
<td>5</td>
<td>6.7</td>
</tr>
<tr>
<td></td>
<td>3</td>
<td>5.5</td>
<td>5</td>
<td>8.9</td>
</tr>
<tr>
<td>Total</td>
<td>72</td>
<td>100</td>
<td>75</td>
<td>100</td>
</tr>
<tr>
<td></td>
<td>55</td>
<td>100</td>
<td>56</td>
<td>100</td>
</tr>
</tbody>
</table>
Table 3: Adherence by treatment cycle at baseline, during the intervention period, and during both follow-up periods.

<table>
<thead>
<tr>
<th>Treatment cycle</th>
<th>Baseline period (N=123)</th>
<th>Intervention period (N=123)</th>
<th>1-6-month follow-up (N=110)</th>
<th>7-24-month follow-up (N=110)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Incentives</td>
<td>Control, (N=52)</td>
<td>Incentives</td>
<td>Control, (N=52)</td>
</tr>
<tr>
<td>N</td>
<td>Mean adherence</td>
<td>N</td>
<td>Mean adherence</td>
<td>N</td>
</tr>
<tr>
<td>1/52</td>
<td>2</td>
<td>54%</td>
<td>1</td>
<td>45%</td>
</tr>
<tr>
<td>2/52</td>
<td>49</td>
<td>67%</td>
<td>27</td>
<td>68%</td>
</tr>
<tr>
<td>3/52</td>
<td>4</td>
<td>76%</td>
<td>3</td>
<td>66%</td>
</tr>
<tr>
<td>4/52</td>
<td>12</td>
<td>76%</td>
<td>16</td>
<td>66%</td>
</tr>
<tr>
<td>5/52</td>
<td>n/a</td>
<td>n/a</td>
<td>n/a</td>
<td>n/a</td>
</tr>
<tr>
<td>Variable cycle</td>
<td>4</td>
<td>60%</td>
<td>5</td>
<td>62%</td>
</tr>
</tbody>
</table>

Note: n/a = not applicable